ASH 2019 Annual Meeting Highlights in MDS

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: January 07, 2020
Expiration Date: January 07, 2021

Expected time to complete this activity as designed: 60 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, participants will hear key highlights taken from of a select group of abstracts which focused on some of the most impactful data in myelodysplastic syndromes (MDS), presented at the 2019 American Society of Hematology (ASH) 61st Annual Meeting. Leading experts in the field of MDS will share their insights on a variety of abstracts, covering topics including, but not limited to: venetoclax therapy in MDS, magrolimab with azacitidine, rigosertib with azacitidine, and enasidenib in patients with high-risk IDH2-mutated MDS.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with myelodysplastic syndromes (MDS)
  • Outline clinical trials and recent advances in the management of serious disease-related conditions in MDS
  • Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in MDS


Activity of Venetoclax-Based Therapy in MDS – Jorge E. Cortes, MD

Ongoing Phase 1b of First-in-Class Anti CD47 Antibody Magrolimab in Combination with Azacitidine – Guillermo Garcia-Manero, MD

Combination Treatment with Lenalidomide-Epoetin Alfa in Low-risk Non-del(5q) MDS: Final Results of the E2905 Intergroup Phase 3 Study – Alan F. List, MD

Assessment of Longer-Term Efficacy and Safety in the Phase 3 MEDALIST Trial – Alan F. List, MD

Oral Rigosertib Combined with Azacitidine as First-Line Therapy in Patients with Higher-Risk MDS: Report of a Phase 2 Study – Shyamala C. Navada, MD, MSCR

Phase 2/3 Study of Oral Rigosertib and Injectable Azacitidine versus Injectable Azacitidine in Treatment-Naïve Patients with Higher-Risk MDS – Shyamala C. Navada, MD, MSCR

Phase 2 Study of Enasidenib in Patients with High-Risk IDH2-Mutated MDS: Preliminary Results – Eytan M. Stein, MD

Instructions for Participation and Credit

This activity is eligible for credit through January 7, 2021. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Jorge E. Cortes, MD
Georgia Cancer Center
Augusta University
August, Georgia

Dr. Jorge Cortes received his medical degree from the Universidad Nacional Autonoma de Mexico, Mexico City. He recently joined Augusta University as the Director of the Georgia Cancer Center in Augusta, Georgia, after being at The University of Texas MD Anderson Cancer Center since 1991 where he had taken on many roles in the Department of Leukemia, Division of Cancer Medicine; including Deputy Department Chair, Chair of AML and CML Sections, Professor of Medicine and Internist. He holds the title of Jane and John Justin Distinguished Chair in Leukemia Research and is the Leukemia Fellowship Program Director.

As Director, Dr. Cortes continues the Georgia Cancer Center’s mission of obtaining National Cancer Institute (NCI) designation, while keeping the mission of ‘reducing the burden of cancer in the State of Georgia and across the globe through superior care, innovation and education’ at the forefront of all endeavors. He has over 230 grants and contracts where he was principal investigator. Dr. Cortes has authored nearly 1,000 peer-review original research articles with numerous other accolades towards his name and practice.

Guillermo Garcia-Manero, MD
Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Guillermo Garcia-Manero received his medical degree and training at the University of Zaragoza in Spain and at the Royal Free Hospital in London. He completed his internship and residency in internal medicine at Thomas Jefferson University Hospital in Philadelphia. He continued his training with a fellowship in hematology and medical oncology at the Cardeza Foundation for Hematology Research, Sidney Kimmel Cancer Center, and Thomas Jefferson University Hospital, where he served as chief fellow. Dr. Garcia-Manero is currently a Professor in the Department of Leukemia and the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research at the University of Texas MD Anderson Cancer Center. He also serves as the Chief of the Section of Myelodysplastic Syndromes, Vice Chairman for Translational Research, Leader of the AML/MDS Moon Shot Program, and Program Director of the Leukemia Fellowship Program.

Dr. Garcia-Manero’s focus is on understanding the cellular and molecular biology of MDS and AML with an aim to improve therapeutic options for these patients. His work has been funded by NIH, DoD, LLS, CPRIT, and the MDS/AML Moon Shot project. He is currently PI/Co-PI on over 25 active AML/MDS clinical trials and has coauthored more than 682 manuscripts. Dr. Garcia-Manero directs one of the largest single institution units for patients with MDS and maintains one of the busiest clinics at MD Anderson. He has trained over 100 fellows and post-doctoral fellows and has been a speaker at multiple national and international forums. He has received numerous awards, including the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research and the Emil J. Freireich Award for Excellence in Translational Research. Dr. Garcia-Manero has also been recognized as one of the Best Doctors in America each year since 2007.

Alan F. List, MD
Professor, Department of Oncologic Sciences
College of Medicine, University of South Florida
Tampa, Florida

Dr. Alan List received his medical degree from the University of Pennsylvania College of Medicine. He completed his internship and residency in internal medicine at Good Samaritan Medical Center, Phoenix, and his oncology and hematology fellowships at Vanderbilt University Medical Center, Nashville. Dr. List is a Professor in the Department of Oncologic Sciences, College of Medicine, at the University of South Florida in Tampa.

Dr. List is a National Board of Medical Examiners and American Board of Internal Medicine (ABIM) diplomat with an oncology and hematology subspecialty. He holds membership in the American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, Southwestern Oncology Group, and the Florida Society of Clinical Oncology (FLASCO). In addition, Dr. List is an ad hoc reviewer for Blood, New England Journal of Medicine, Cancer, Leukemia Research, Oncogene, Journal of Clinical Oncology, Cancer Research, Cell, and Leukemia, among others. He holds more than 20 patents, and has written and presented hundreds of journal articles and abstracts. Dr. List is internationally recognized for his many contributions in the development of novel and effective treatment strategies for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Shyamala C. Navada, MD, MSCR
Assistant Professor
Mount Sinai School of Medicine
Department of Medicine
Division of Hematology/Oncology
New York, New York

Dr. Shyamala Navada received her medical degree from the University of Illinois College of Medicine in Chicago, as well as a master’s of science in clinical research from Mount Sinai School of Medicine in New York City. She completed a medical residency at the University of Michigan Hospitals and a hematology/oncology fellowship at Mount Sinai School of Medicine. Dr. Navada is Assistant Professor at Mount Sinai School of Medicine, Department of Medicine, Division of Hematology/Oncology, she is also an Assistant Attending Physician at Mount Sinai Beth Israel.

Dr. Navada is board certified in hematology and medical oncology. Her academic career in clinical and translational research in myelodysplastic syndromes (MDS) focuses on designing early phase trials investigating the role of novel candidate drugs to improve the outcome of patients with MDS and acute myeloid leukemia (AML). Her clinical expertise is in the medical management of MDS AML, and she also manages patients with benign hematologic conditions, such as cytopenias. As a result of her academic and research activities, Dr. Navada has presented at national and international meetings, including the American Society of Hematology, International Bone Marrow Failure Disease Scientific Symposium, International Symposium on Myelodysplastic Syndromes, and the European Hematology Association Congress. In addition, she is the author/co-author of medical textbook chapters and articles in peer-reviewed journals, including The Journal of Clinical Investigation and Leukemia Research.

Eytan M. Stein, MD
Assistant Professor
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Eytan Stein received his medical degree from Northwestern University in Chicago, where he also completed his internal medicine residency. He then completed his fellowships in medicine at Weill Cornell Medical College, and in medical oncology and hematology at Memorial Sloan Kettering. He is an Assistant Professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City.

Dr. Stein holds board certification from the American Board of Internal Medicine, American Board of Clinical Oncology, and the American Board of Hematology. He focuses his practice on the treatment of acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. His research interests include developing novel, early phase clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies.


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-20-003-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 20-003-114


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Jorge Cortes has received honoraria as a consultant and grant support related to research activities from FORMA Therapeutics, Inc. and Jazz Pharmaceuticals plc.

Dr. Guillermo Garcia-Manero has received honoraria as a consultant from Amphivena Therapeutics, Inc., Astex Pharmaceuticals, and Celgene Corporation. He has received grant support related to research activities from AbbVie Inc., Amphivena, Astex, Celgene, H3 Biomedicine Inc., Helsinn Healthcare SA, Merck & Co., Inc., Novartis AG, and Onconova Therapeutics.

Dr. Alan List has received honoraria as a consultant as well as grant support related to research activities from Celgene Corporation.

Dr. Shyamala Navada has received grant support related to research activities from Onconova Therapeutics.

Dr. Eytan Stein has received honoraria related to formal advisory activities from Agios, Amgen Inc., Astellas Pharma US, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Genentech, Inc., Novartis AG, PTC Therapeutics, Seattle Genetics, Inc., and Syros Pharmaceuticals, Inc. He has received grant support related to research activities from Agios, Amgen, Bayer AG, BioTheryX, Inc., Celgene, and Syndax Pharmaceuticals, Inc. He also owns significant holdings in Auron Therapeutics.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology.

©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.